Dasatinib is one of the second-generation tyrosine kinase inhibitors used to treat chronic myeloid leukemia and has a broad target spectrum, including KIT, PDGFR, and SRC family kinases. Here, PDGFRB is linked to chronic myelogenous leukemia, BCR-ABL1 positive.